RSV Diagnostics Market To Reach $1.2 Billion By 2022: Grand View Research, Inc.

13 Jan, 2016, 08:15 ET from Grand View Research, Inc.

SAN FRANCISCO, January 13, 2016 /PRNewswire/ --

Global Respiratory Syncytial Virus (RSV) diagnostics market is expected to reach USD 1.2 billion by 2022, according to a new study by Grand View Research Inc. Increasing neonatal population suffering from respiratory conditions including RSV infections and supportive initiatives for diagnosis of newborns by the healthcare providers are expected to be vital impact rendering drivers for RSV diagnostics market.

     (Logo: http://photos.prnewswire.com/prnh/20150105/723757)

According to the statistics provided by the WHO, hospitalization of over 150,000 children (below the age of five) and about 14,000 deaths in geriatric patients occurred in the U.S. in 2014 due to RSV infections. This is anticipated to trigger demand for testing of these conditions over the forecast period.

Browse full research report with TOC on "Respiratory Syncytial Virus Diagnostics Market Analysis By Product (Direct Fluorescent Antibody (DFA), Rapid Antigen Diagnostic Tests (RADTs), Molecular Diagnostics, Chromatographic Immunoassay, Diagnostic Imaging, Gel Microdroplets, Flow Cytometry), By End-use (Hospitals, Laboratory, Clinics, Homecare) And Segment Forecasts To 2022" at: http://www.grandviewresearch.com/industry-analysis/respiratory-syncytial-virus-diagnostics-market                                                                                                                                                                        

Furthermore, the global birth rate as of 2014 is 18.7 births per 1,000 individuals, which is predicted to increase the infant population substantially over the next seven years. According to the statistics, it is estimated that about 134.2 million births took place in 2014, which are prone to RSV infections and require diagnosis, thus forming a large market base.

In 2010, Save Babies Through Screening Foundation (SBTS) entered in a partnership with World Solutions Against Infectious Disease (WSAID) as an attempt to promote higher screening of newborns for infectious diseases, metabolic disorders, and hearing disabilities.

Further key findings from the report suggest: 

  • Chromatographic immunoassay technology based products are expected to witness the fastest growth at a CAGR above 10.0% over the next seven years owing to their higher specificity than molecular diagnostic products. The commercially available test kits include Binax Now RSV, QuickLab RSV Test, Remel Xpect, and RSV Respi-Strip.
  • Hospitals are predicted to dominate the RSV diagnostics market followed by home care. Together, they are expected to contribute over 50.0% of the market share in 2022. Increasing demand for home care diagnostic devices by patients is anticipated to drive growth of the segment over the next seven years.
  • North America is anticipated to dominate the market and contribute a revenue share of over 40.0% by 2022. Rising awareness among the population base and favorable initiatives by the government agencies such as the WHO, PAHO, and WSAID to initiate and implement newborn screening are expected to drive growth.
  • Key players of the market include Alere Inc., EMD Millipore, BD and Company, Ortho Clinical Diagnostics, Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific Inc. CLIA waiver and launch of RSV assays by companies like Roche Diagnostics, Becton Dickinson and Company, and Alere Inc. are expected to boost market growth over the forecast period.

Grand View Research has segmented the Global Respiratory Syncytial Virus diagnostics market on the basis of products, end-use, and region:

  • RSV Diagnostics Market Product Outlook (Revenue, USD Million, 2012 - 2022) 
    • Direct Fluorescence Antibody (DFA) Method
    • Rapid Antigen Diagnostic Tests (RADTs)
    • Molecular Diagnostics
    • Chromatographic Immunoassay
    • Diagnostic Imaging
    • Gel Microdroplets
    • Flow Cytometry
    • Others
  • RSV Diagnostics Market End-use Outlook (Revenue, USD Million, 2012 - 2022) 
    • Hospitals
    • Laboratory
    • Clinics
    • Homecare
  • RSV Diagnostics Market Regional Outlook (Revenue, USD Million, 2012 - 2022) 
    • North America
      • U.S.
      • Canada
    • Europe
      • UK
      • Germany
      • France
      • Spain
      • Italy
    • Asia Pacific
      • Japan
      • China
      • India
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Peru
    • MEA
      • South Africa
      • Saudi Arabia

Browse related reports by Grand View Research: 





About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Read Our Blogs - dniamericas.org, ni2014.org        

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email:sales@grandviewresearch.com

Web: http://www.grandviewresearch.com  


SOURCE Grand View Research, Inc.